Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically or cytologically-confirmed, locally advanced, or metastatic solid malignancy that is relapsed, refractory, or progressing following at least 1 prior systemic therapy (Part A)~* Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST 1.1~* Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1~* Patients in Part B must have histologically or cytologically-confirmed, locally-advanced, or metastatic solid malignancy within the disease indications of Part A~* Adequate baseline hematologic, renal, and hepatic function~* Patients for whom there is no further standard therapy available at the time of enrollment (Part A)~* Patients with a histologically-confirmed, advanced solid malignancy meeting one of the following criteria: (1) indication for which pembrolizumab is approved or (2) relapsed, refractory, or progressive disease following at least 1 prior therapy and for which no further standard therapy is a available (Parts C and D)~Exclusion Criteria:~* Patients with carcinomatous meningitis or active central nervous system (CNS) metastases~* Patients with recent (within 14 days) or serious ongoing infection~* Patients requiring systemic treatment with corticosteroids (greater than 10 mg prednisone equivalents) or immunosuppressive medications within 14 days of enrollment~* Patients with active known or suspected autoimmune disease or significant autoimmune-related toxicity from prior immuno-oncology therapy~* Known active or latent tuberculosis~* Uncontrolled diabetes mellitus~* History of interstitial lung disease~* Gastrointestinal abnormality that would affect absorption of SGN-2FF~* Patients tested positive for hepatitis B or with a known, active hepatitis C infection~* Women who are pregnant or breastfeeding~* Patients with deep vein thrombosis (DVT)~* Contraindication to prophylactic anticoagulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGN-2FF (Type: EXPERIMENTAL): Dose escalation and dose expansion
- SGN-2FF and Pembrolizumab (Type: EXPERIMENTAL): Dose escalation and dose expansion

Based on this trial design, predict the completion outcome and termination type (if applicable).